FDA Approves Blinatumomab for Advanced Leukemia Treatment
WASHINGTON, D.C. — On Friday, the Food and Drug Administration (FDA) approved blinatumomab (Blincyto, Amgen Inc.) for both adult and pediatric patients one month and older with CD19-positive Philadelphia chromosome-negative …
FDA Approves Blinatumomab for Advanced Leukemia Treatment Read More